High regional variability of HIV, HCV and injecting risks among people who inject drugs in Poland: comparing a cross-sectional bio-behavioural study with case-based surveillance

BMC Infectious Diseases

Lucas Wiessing¹  Janusz Sierosławski³  Magdalena Rosińska² 

[1] European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), Cais do Sodré, Lisbon, 1249-289, Portugal;Department of Epidemiology, National Institute of Public Health, National Institute of Hygiene, Chocimska 24, Warsaw, 00-791, Poland;Institute of Psychiatry and Neurology, Sobieskiego 9, Warsaw, 02-957, Poland

关键词: Surveillance;    Prevalence;    HIV;    HCV;    Injecting drug use;    People who inject drugs;   

Others  :  1132622
DOI  :  10.1186/s12879-015-0828-9

 received in 2014-09-03, accepted in 2015-02-11,  发布年份 2015

【 摘 要 】

Background

People who inject drugs (PWID) are an important group at risk of blood borne infections in Poland. However, robust evidence regarding the magnitude of the problem and geographical variation is lacking, while coverage of prevention remains low. We assessed the potential of combining bio-behavioural studies and case-based surveillance of PWID to gain insight into preventive needs in Poland.

Methods

Results of a bio-behavioural human immunodeficiency virus (HIV) and hepatitis C virus (HCV) prevalence study among ever injectors in six regions in Poland were compared with HIV case-based surveillance trends from 2000 to 2012. Logistic regression was used for multivariable analyses in the prevalence study. The case surveillance data were correlated with prevalence data, by region, to determine surveillance validity and identify any recent trends.

Results

HIV seroprevalence (18% overall) differed more than ten-fold across regions (2.4% to 32%), but HCV seroprevalence and the proportion of PWID sharing needles/syringes in the past 12 months were similar, 44% to 68% and 22% to 29%, respectively. In multivariable models accounting for socio-demographic factors, duration of injecting history and needle sharing practices, regional differences were significant for both HIV and HCV seroprevalence with adjusted odds ratios varying up to a factor of 12.6 for HIV and 3.8 for HCV. The number of new cases of HIV diagnosed in each region during the bio-behavioural study period was strongly correlated (r = 0.93) with HIV prevalence. There was an overall decreasing trend in the number of new diagnoses of HIV over time. However, a transient increase in three regions was preceded by a higher proportion of people with short injecting history (≤5 years) and a high prevalence of HCV coinciding with a low prevalence of HIV in the bio-behavioural study.

Conclusions

Bio-behavioural and case-based data were consistent with respect to the regional distribution of HIV and also provided complementary information, with the proportion of new injectors and high HCV prevalence predicting increases in HIV case rates. We identified three regions in Poland that appear to be at increased need for preventive measures. Data point to the need for a stronger investment in harm reduction programmes in Poland.

【 授权许可】

   
2015 Rosińska et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Mathers BM, Degenhardt L, Phillips B, Wiessing L, Hickman M, Strathdee SA, et al.: 2007 Reference Group to the UNon HIV and Injecting Drug Use:HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage. Lancet 2010, 375:1014-28.
• [2]McCoy CB, Rodriguez F: Global overview of injection drug use and HIV infection. Lancet 2005, 365:1008-9.
• [3]Nelson PK, Mathers BM, Cowie B, Hagan H, Des Jarlais D, Horyniak D, et al.: Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 2011, 378:571-83.
• [4]European Centre for Disease Prevention and Control/WHO RegionalOffice for Europe: HIV/AIDS surveillance in Europe 2012. European Centre for Disease Prevention and Control, Stockholm; 2013.
• [5]Hedrich D, Kalamara E, Sfetcu O, Pharris A, Noor A, Wiessing L, et al.: Human immunodeficiency virus among people who inject drugs: is riskincreasing in Europe? Euro Surveill 2013, 18:20648.
• [6]Fotiou A, Micha K, Paraskevis D, Terzidou M, Malliori M, Hatzakis A: HIV outbreak among injecting drug users in Greece. An updated brief report for the EMCDDA on the recent outbreak of HIV infections among drug injectors in Greece. European Monitoring Centre for Drugs and Drug Addiction, Lisbon; 2012.
• [7]Botescu A, Abagiu A, Mardarescu M, Ursan M: HIV/AIDS among injecting drug users in Romania. Report of a recent outbreak and initial response policies. European Monitoring Centre for Drugs and Drug Addiction, Lisbon; 2012.
• [8]European Monitoring Centre for Drugs and Drug Addiction and European Centre for Disease Prevention and Control: HIV in injecting drug users in the EU/EEA, following a reported increase of cases in Greece and Romania. European Monitoring Centre for Drugs and Drug Addiction and European Centre for Disease Prevention and Control, Lisbon; 2012.
• [9]Pharris A, Wiessing L, Sfetcu O, Hedrich D, Botescu A, Fotiou A, et al. Human immunodeficiency virus in injecting drug users in Europe following a reported increase of cases in Greece and Romania, 2011. Euro Surveill. 2011, 16, pii: 20032. http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20032.
• [10]Committee on the Prevention of HIV Infection Among Injecting Drug Users in High-Risk Countries. Preventing HIV Infection Among Injecting Drug Users in High-Risk Countries: An Assessment of the Evidence. Washington, DC, USA: National Academy of Sciences. [http://www.nap.edu/catalog/11731/preventing-hiv-infection-among-injecting-drug-users-in-high-risk-countries]
• [11]Gowing LR, Farrell M, Bornemann R, Sullivan LE, Ali RL: Methadone treatment of injecting opioid users for prevention of HIV infection. J Gen Intern Med 2006, 21:193-5.
• [12]Metzger DS, Navaline H, Woody GE: Drug abuse treatment as AIDS prevention. Public Health Rep 1998, 113(Suppl 1):97-106.
• [13]Sullivan LE, Moore BA, Chawarski MC, Pantalon MV, Barry D, O'Connor PG, et al.: Buprenorphine/naloxone treatment in primary care is associated with decreased human immunodeficiency virus risk behaviors. J Subst Abuse Treat 2008, 35:87-92.
• [14]van den Berg C, Smit C, Van Brussel G, Coutinho R, Prins M, Amsterdam C: Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users. Addiction 2007, 102:1454-62.
• [15]Turner KM, Hutchinson S, Vickerman P, Hope V, Craine N, Palmateer N, et al.: The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence. Addiction 2011, 106:1978-88.
• [16]Dutta A, Wirtz AL, Baral S, Beyrer C, Cleghorn FR: Key harm reduction interventions and their impact on the reduction of risky behavior and HIV incidence among people who inject drugs in low-income and middle-income countries. Curr Opin HIV AIDS 2012, 7:362-8.
• [17]Wiessing L, Likatavičius G, Klempová D, Hedrich D, Nardone A, Griffiths P: Associations Between Availability and Coverage of HIV-Prevention Measures and Subsequent Incidence of Diagnosed HIV Infection Among Injection Drug Users. Am J Public Health 2009, 99:1049-52.
• [18]Uusküla A, Raag M, Folch C, Prasad L, Karnite A, van Veen MG, et al. Self-reported testing, HIV status and associated risk behaviours among people who inject drugs in Europe - important differences between East and West. AIDS 2014. In press.
• [19]Sierosławski, J. Estimation of prevalence of problem drug use and analysis of the patterns of drug use and associated problems [In Polish]. [http://www.kbpn.gov.pl/portal?id=459814]
• [20]Malczewski A, Struzik M. (eds). Annual Report 2012 Poland: Drug Situation. [http://www.kbpn.gov.pl/portal?id=111319]
• [21]Malczewski A (ed.):Annual Report 2010 Poland: Drug Situation. [http://www.cinn.gov.pl/portal?id=105923]
• [22]Reintjes R, Wiessing L: 2nd-generation HIV surveillance and injecting drug use: uncovering the epidemiological ice-berg. Int J Public Health 2007, 52:166-72.
• [23]World Health Organization and UNAIDS. Guidelines for second generation HIV surveillance: The next decade.Geneva: WHO and UNAIDS; 2000. [http://www.who.int/hiv/pub/surveillance/en/cds_edc_2000_5.pdf]
• [24]Spina A, Eramova I, Lazarus JV: Policy responses to viral hepatitis B and C among people who inject drugs in Member States of the WHO European region: a sub-analysis of the WHO 2013 global hepatitis policy survey. BMC Infect Dis 2014, 14(Suppl 6):S15. BioMed Central Full Text
• [25]Kretzschmar M, Zhang W, Mikolajczyk RT, Wang L, Sun X, Kraemer A, et al.: Regional differences in HIV prevalence among drug users in China: potential for future spread of HIV? BMC Infect Dis 2008, 8:108. BioMed Central Full Text
• [26]Vickerman P, Martin NK, Hickman M: Understanding the trends in HIV and hepatitis C prevalence amongst injecting drug users in different settings–implications for intervention impact. Drug Alcohol Depend 2012, 123:122-31.
• [27]Czerwinski M, McNutt LA, DeHovitz JA, Zielinski A, Rosinska M: Refining HIV risk: the modifying effects of youth, gender and education among people who inject drugs in Poland. PLoS One 2013, 8:e68018. doi:10.1371/journal.pone.0068018
• [28]Van Kerckhoven I, Vercauteren G, Piot P, van der Groen G: Comparative evaluation of 36 commercial assays for detecting antibodies to HIV. Bull World Health Organ 1991, 69:753-60.
• [29]Pawlotsky JM: Diagnostic tests for hepatitis C. J Hepatol 1999, 31(Suppl 1):71-9.
• [30]Little RJA, Rubin DB: Statistical Analysis with Missing Data. J. Wiley & Sons, New York; 1987.
• [31]Royston P: Multiple imputation of missing values: further update of ice, with an emphasis on interval censoring. Stata J 2007, 7:445-64.
• [32]Malczewski A, Struzik M, Jaśkiewicz A. First national survey low-thresholds clients and services in 2008. Study report. [http://www.cinn.gov.pl/portal?id=166055]
• [33]Lardelli P, de la Fuente L, Alonso JM, López R, Bravo MJ, Delgado-Rodríguez M: Geographical variations in the prevalence of HIV infection among drug users receiving ambulatory treatment in Spain. Int J Epidemiol 1993, 22:306-14.
• [34]Lorvick J, Kral AH, Seal K, Gee L, Edlin BR: Prevalence and duration of hepatitis C among injection drug users in San Francisco, Calif. Am J Public Health 2001, 91:46-7.
• [35]Rhodes T, Platt L, Maximova S, Koshkina E, Latishevskaya N, Hickman M, et al.: Prevalence of HIV, hepatitis C and syphilis among injecting drug users in Russia: a multi-city study. Addiction 2006, 101:252-66.
• [36]Hagan H, Des Jarlais DC, Stern R, Lelutiu-Weinberger C, Scheinmann R, Strauss S, et al.: HCV Synthesis Project: Preliminary analyses of HCV prevalence in relation to age and duration of injection. Int J Drug Policy 2007, 18:341-51.
• [37]Roy E, Alary M, Morissette C, Leclerc P, Boudreau JF, Parent R, et al.: High hepatitis C virus prevalence and incidence among Canadian intravenous drug users. Int J STD AIDS 2007, 18:23-7.
• [38]Xia X, Luo J, Bai J, Yu R: Epidemiology of hepatitis C virus infection among injection drug users in China: systematic review and meta-analysis. Public Health 2008, 122:990-1003.
• [39]Dumchev KV, Soldyshev R, Qian HZ, Zezyulin OO, Chandler SD, Slobodyanyuk P, et al.: HIV and hepatitis C virus infections among hanka injection drug users in central Ukraine: a cross-sectional survey. Harm Reduct J 2009, 6:23. BioMed Central Full Text
• [40]Rondinelli AJ, Ouellet LJ, Strathdee SA, Latka MH, Hudson SM, Hagan H, et al.: Young adult injection drug users in the United States continue to practice HIV risk behaviors. Drug Alcohol Depend 2009, 104:167-74.
• [41]Lindenburg CE, Krol A, Smit C, Buster MC, Coutinho RA, Prins M: Decline in HIV incidence and injecting, but not in sexual risk behaviour, seen in drug users in Amsterdam: a 19-year prospective cohort study. AIDS 2006, 20:1771-5.
• [42]Falster K, Kaldor JM, Maher L: Collaboration of Australian Needle and Syringe Programs: Hepatitis C virus acquisition among injecting drug users: a cohort analysis of a national repeated cross-sectional survey of needle and syringe program attendees in Australia, 1995–2004. J Urban Health 2009, 86:106-18.
• [43]Rhodes T, Treloar C: The social production of hepatitis C risk among injecting drug users: a qualitative synthesis. Addiction 2008, 103:1593-603.
• [44]Small W, Kerr T, Charette J, Schechter MT, Spittal PM: Impacts of intensified police activity on injection drug users: Evidence from an ethnographic investigation. Int J Drug Policy 2006, 17:85-95.
• [45]Shannon K, Rusch M, Shoveller J, Alexson D, Gibson K, Tyndall MW, et al.: Mapping violence and policing as an environmental-structural barrier to health service and syringe availability among substance-using women in street-level sex work. Int J Drug Policy 2008, 19:140-7.